Resolutions at the annual general meeting in Medivir on 5 May 2015

Election of the board of directors and auditor
The annual general meeting in Medivir Aktiebolag (publ) on 5 May 2015 resolved,
in accordance with the nomination committee's proposal, that the number of board
members shall be seven with no deputy board members. Anders Hallberg, Anna Malm
Bernsten, Birgitta Stymne Göransson, Anders Ekblom and Bertil Samuelsson were re
-elected as board members and Johan Harmenberg and Helena Levander were elected
as new board members. Birgitta Stymne Göransson was re-elected chairman of the
board. PricewaterhouseCoopers AB was re-elected as auditor.

Remuneration to the board of directors
The annual general meeting also resolved on remuneration to the board of
directors in accordance with the nomination committee's proposal. The
remuneration to the board shall amount to not more than SEK 2,750,000 allocated
as follows. The chairman shall receive SEK 575,000 and the other members
entitled to remuneration shall receive SEK 240,000 each. Remuneration for work
performed in relation to committees shall be paid in a total amount of SEK
735,000, whereof SEK 210,000 shall be allocated to the audit committee (whereof
SEK 80,000 to the convener of the committee and SEK 65,000 to each of the other
two members), SEK 115,000 to the remuneration committee (whereof SEK 65,000 to
the convener of the committee and SEK 50,000 to the other member) and SEK
410,000 to the R&D committee (whereof SEK 90,000 to the convener of the
committee and SEK 80,000 to each of the other four members).

Remuneration guidelines for senior executives
The annual general meeting approved the proposal of the board of directors on
remuneration guidelines for senior executives. Under the guidelines, the company
shall offer a total remuneration on market norms and enable skilled senior
executives to be hired and retained. The remuneration to senior executives may
consist of basic salary, variable salary, incentive programmes resolved by the
general meeting, pension and other benefits.

Authorisation to issue new shares
The annual general meeting resolved, in accordance with the nomination
committee's proposal, to authorise the board, for the period up to the next
annual general meeting, to adopt decisions, whether on one or several occasions
and whether with or without pre-emption rights for the shareholders, to issue
new shares of class B to an amount not exceeding in total 10 per cent of the
total number of outstanding class B-shares in the company following utilization
of the authorisation. New issue may be made with or without provisions
concerning non-cash consideration, set-off or other provision specified in
Chapter 13 Section 5, first paragraph, 6, of the Swedish Companies Act. The
purpose of the authorisation is to provide the board with flexibility in its
work to secure that the company, in a suitable way, can be provided with capital
for the financing of the business, acquisitions of companies and products, and
to enable a broadening of the ownership of the company.

Nomination committee
The annual general meeting resolved to appoint a nomination committee for the
annual general meeting 2016 substantially in accordance with the same procedure
as the preceding year. In brief, this entails that the chairman of the board
shall contact the three largest shareholders in respect of voting power by the
end of the third quarter. These three shareholders shall be offered to appoint
one representative each for the nomination committee. In addition, the chairman
of the board shall be included as a member of the nomination committee.

Authorisation to repurchase and transfer shares
The annual general meeting resolved to authorize the board of directors to
resolve to repurchase, on one or several occasions until the next annual general
meeting, as many own shares as may be purchased without the company’s holding at
any time exceeding 10 per cent of the total number of shares in the company.
Further, it was resolved to authorize the board of directors to resolve, on one
or several occasions until the next annual general meeting, to transfer (sell)
own shares.

The purpose of the authorisation to repurchase own shares is to promote an
efficient capital usage and ownership structure in the company and to provide
flexibility as regards the company’s possibilities to distribute capital to its
shareholders. The purpose of the authorisation to transfer own shares is to
enable the board of directors to make acquisitions of companies and products, a
broadening of the ownership of the company or for use in the context of the
company’s incentive programmes.

Long-term incentive programme
The board of directors withdrew its proposal on the renewal of the long-term
incentive programme. No resolution was adopted.

Approval of profit and loss accounts and balance sheets, and discharge from
liability of the board members and the managing director
The profit and loss account and balance sheet as well as the consolidated profit
and loss account and consolidated balance sheet were approved, and the managing
director and the board members were discharged from liability with respect to
their respective management of the company for financial year 2014.

Appropriation of the company’s profit or loss
The annual general meeting resolved, in accordance with the board's proposal,
that the company’s results shall be carried forward.

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0)725-480 580.

Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 16.45 CET on 5 May 2015.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a growing portfolio of specialty care
pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm
Mid Cap List.